Cargando…
Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
INTRODUCTION: Switching to an alternative anti-vascular endothelial growth factor (anti-VEGF) agent has been suggested for patients with neovascular age-related macular degeneration (nAMD) who have a suboptimal response to initial therapy. However, post hoc analyses of some studies have shown that c...
Autores principales: | Tuerksever, Cengiz, Somfai, Gábor Márk, Oesch, Susanne, Machewitz, Tobias, Hasler, Pascal W., Zweifel, Sandrine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784022/ https://www.ncbi.nlm.nih.gov/pubmed/35066801 http://dx.doi.org/10.1007/s40123-021-00448-w |
Ejemplares similares
-
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
por: Wolf, Sebastian, et al.
Publicado: (2022) -
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
por: Chaudhary, Varun, et al.
Publicado: (2022) -
Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR
por: Freund, K. Bailey, et al.
Publicado: (2022) -
High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
por: Tuerksever, Cengiz, et al.
Publicado: (2021) -
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)